MANKIND PHARMA Financial Statement Analysis
|
||
|
The Revenues of MANKIND PHARMA have increased by 12.44% YoY .
The Earnings Per Share (EPS) of MANKIND PHARMA has decreased by -10.56 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
MANKIND PHARMA Last 5 Annual Financial Results
[BOM: 543904|NSE : MANKIND]
| Consolidated | Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 |
|---|---|---|---|---|---|
| Revenues | ₹8,749 Cr | ₹7,782 Cr | ₹6,214 Cr | ₹5,872 Cr | ₹4,980 Cr |
| Expenses | ₹6,848 Cr | ₹5,791 Cr | ₹4,565 Cr | ₹4,427 Cr | ₹4,055 Cr |
| Operating Profit (Excl OI) | ₹1,902 Cr | ₹1,991 Cr | ₹1,649 Cr | ₹1,445 Cr | ₹925 Cr |
| Other Income | ₹129 Cr | ₹196 Cr | ₹171 Cr | ₹104 Cr | ₹53 Cr |
| Interest | ₹46 Cr | ₹60 Cr | ₹21 Cr | ₹23 Cr | ₹44 Cr |
| Depreciation | ₹326 Cr | ₹167 Cr | ₹119 Cr | ₹99 Cr | ₹69 Cr |
| Profit Before Tax | ₹1,671 Cr | ₹1,975 Cr | ₹1,692 Cr | ₹1,438 Cr | ₹875 Cr |
| Profit After Tax | ₹1,310 Cr | ₹1,453 Cr | ₹1,293 Cr | ₹1,056 Cr | ₹610 Cr |
| Consolidated Net Profit | ₹1,282 Cr | ₹1,433 Cr | ₹1,265 Cr | ₹1,030 Cr | ₹579 Cr |
| Earnings Per Share (Rs) | ₹32.00 | ₹35.78 | ₹31.59 | ₹25.72 | ₹14.44 |
| PAT Margin (%) | 14.38 | 18.00 | 20.00 | 17.31 | 12.26 |
| ROE(%) | 19.27 | 26.72 | 31.51 | 33.48 | 21.41 |
| ROCE(%) | 23.49 | 33.96 | 39.97 | 43.57 | 28.80 |
| Total Debt/Equity(x) | 0.02 | 0.14 | 0.05 | 0.04 | 0.10 |
Key Financials |
||
| Market Cap | : | ₹ 87,330.8 Cr |
| Revenue (TTM) | : | ₹ 9,946.3 Cr |
| Net Profit(TTM) | : | ₹ 1,743.3 Cr |
| EPS (TTM) | : | ₹ 43.5 |
| P/E (TTM) | : | 50.1 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| MANKIND PHARMA | -6.6% | -6.6% | NA |
| SUN PHARMACEUTICAL INDUSTRIES | 0.2% | -6.1% | 55.7% |
| CIPLA | -2.5% | -5.1% | 48.6% |
| DR REDDYS LABORATORIES | -3.7% | -1.4% | 26% |
| ZYDUS LIFESCIENCES | 1.8% | 2.2% | 88.6% |
| DIVIS LABORATORIES | -0.9% | 5% | 19.2% |
| TORRENT PHARMACEUTICALS | -3.2% | 1.8% | 57.6% |
| LUPIN | -1.9% | 1.8% | 126.8% |
| AUROBINDO PHARMA | -1.6% | 1.1% | 83.7% |
MANKIND PHARMA Revenues
[BOM: 543904|NSE : MANKIND]
| Y-o-Y | 12.44 % |
| 5 Yr CAGR | 15.13 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2023 | ₹8,749 Cr | 12.44 | |
| Mar2022 | ₹7,782 Cr | 25.22 | |
| Mar2021 | ₹6,214 Cr | 5.83 | |
| Mar2020 | ₹5,872 Cr | 17.91 | |
| Mar2019 | ₹4,980 Cr | - | |
MANKIND PHARMA Operating Profit
[BOM: 543904|NSE : MANKIND]
| Y-o-Y | -4.45 % |
| 5 Yr CAGR | 19.75 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2023 | ₹1,902 Cr | -4.45 | |
| Mar2022 | ₹1,991 Cr | 20.70 | |
| Mar2021 | ₹1,649 Cr | 14.15 | |
| Mar2020 | ₹1,445 Cr | 56.18 | |
| Mar2019 | ₹925 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | -15.01 % |
| 5 Yr CAGR | 4.02 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2023 | 21.74% | -15.01 | |
| Mar2022 | 25.58% | -3.62 | |
| Mar2021 | 26.54% | 7.89 | |
| Mar2020 | 24.6% | 32.47 | |
| Mar2019 | 18.57% | - | |
MANKIND PHARMA Profit After Tax
[BOM: 543904|NSE : MANKIND]
| Y-o-Y | -10.58 % |
| 5 Yr CAGR | 22.01 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2023 | ₹1,282 Cr | -10.58 | |
| Mar2022 | ₹1,433 Cr | 13.28 | |
| Mar2021 | ₹1,265 Cr | 22.81 | |
| Mar2020 | ₹1,030 Cr | 78.11 | |
| Mar2019 | ₹579 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | -20.11 % |
| 5 Yr CAGR | 4.07 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2023 | 14.38 % | -20.11 | |
| Mar2022 | 18 % | -10.00 | |
| Mar2021 | 20 % | 15.54 | |
| Mar2020 | 17.31 % | 41.19 | |
| Mar2019 | 12.26 % | - | |
MANKIND PHARMA Earnings Per Share (EPS)
[BOM: 543904|NSE : MANKIND]
| Y-o-Y | -10.56 % |
| 5 Yr CAGR | 22.01 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2023 | ₹32 | -10.56 | |
| Mar2022 | ₹36 | 13.26 | |
| Mar2021 | ₹32 | 22.82 | |
| Mar2020 | ₹26 | 78.12 | |
| Mar2019 | ₹14 | - | |
MANKIND PHARMA Return on Capital Employed (ROCE)
[BOM: 543904|NSE : MANKIND]
| Y-o-Y | -30.83 % |
| 5 Yr CAGR | -4.97 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2023 | 23.49% | -30.83 | |
| Mar2022 | 33.96% | -15.04 | |
| Mar2021 | 39.97% | -8.26 | |
| Mar2020 | 43.57% | 51.28 | |
| Mar2019 | 28.8% | - | |
MANKIND PHARMA Share Price vs Sensex
| Current Share Price | : | ₹2,180.0 |
| Current MarketCap | : | ₹ 87,330.8 Cr |
| Updated EOD on | : | May 08,2024 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| MANKIND PHARMA | -6.6% |
-6.6% |
|
| SENSEX | -1.4% |
-0.6% |
20.1% |
MANKIND PHARMA related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| S&P BSE HEALTHCARE | -1% | -1.1% | 52.2% |
| S&P BSE 100 LARGECAP TMC | -1.2% | -0.1% | 28.5% |
| S&P BSE 250 LARGEMIDCAP | -1.2% | 0.3% | 32.8% |
| S&P BSE LARGECAP | -1.2% | -0.1% | 27.4% |
| S&P BSE 200 | -1.2% | 0.2% | 32.4% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY PHARMA | -0.6% | -1.6% | 49.8% |
| NIFTY 200 | -1.2% | 0.2% | 32.7% |
| NIFTY 500 | -1.4% | 0.5% | 35.5% |
| NIFTY LARGE MIDCAP 250 | -1.4% | 0.6% | 41.2% |
| NIFTY FREE MIDCAP 100 | -1.6% | 0.6% | 55.5% |
You may also like the below Video Courses
FAQ about MANKIND PHARMA Financials
How the annual revenues of MANKIND PHARMA have changed ?
The Revenues of MANKIND PHARMA have increased by 12.44% YoY .
How the Earnings per Share (EPS) of MANKIND PHARMA have changed?
The Earnings Per Share (EPS) of MANKIND PHARMA has decreased by -10.56 % YoY .
Check out Intrinsic Value of Peers of MANKIND PHARMA
Compare Stock Analytics of Peers of MANKIND PHARMA
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
